Quality-of-Life in CRPC Patients Treated With Enzalutamide Versus Abiraterone: Impact of Standard and Modified Dosing.

Clin Genitourin CancerJul 4, 2026 (epub)
Clinical ResearchOncology (Medical)

Shuichi Tatarano, Kouji Izumi, Hideki Enokida et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial compared the quality of life (QoL) in patients with castration-resistant prostate cancer (CRPC) treated with enzalutamide (ENZ) versus abiraterone (ABI). Among 89 patients in each arm, ABI significantly deteriorated QoL over time, while ENZ maintained QoL. The total FACT-G score for ABI worsened with standard dosing (P = .0003), but not with modified dosing.

Key findings

  • ABI significantly deteriorated total FACT-G score over time (P = .0003).
  • ENZ did not change the total FACT-G score during treatment (P = .9585).
  • Standard dose of ABI worsened social and functional well-being (P = .0010 and P < .0001).
  • Modified dose of ABI did not deteriorate social or functional well-being (P = .6549 and P = .5837).

Why it matters

Understanding the impact of different treatments on quality of life is crucial for clinicians managing CRPC. This study highlights that while both treatments offer similar survival benefits, their effects on QoL can differ significantly, influencing treatment choices.

Source

PubMed · PMID 42509097

Published in Clin Genitourin Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.